Lexicon Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Vocabulary Pharmaceuticals, Inc. (previously Lexicon Genetic) a biopharmaceutical organization, centers around the disclosure and improvement of drug items for the treatment of human infection, including immunology, digestion, cardiology, and ophthalmology. The organization's medication competitors incorporate LX1031, which has finished Phase II clinical preliminaries for the treatment of peevish entrail condition and other gastrointestinal problems; LX4211 that has finished Phase II clinical preliminaries to treat type 2 diabetes; LX2931, which is in Phase II clinical preliminaries for the treatment of rheumatoid joint pain and other immune system illnesses; and LX1032 that has finished Phase II clinical preliminaries to treat the side effects related with carcinoid disorder. It likewise has a preclinical improvement drug competitor, LX7101, for the treatment of glaucoma. The organization has drug disclosure coalitions with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It likewise has drug improvement funding cooperation with Symphony Icon; joint effort concurrence with Taconic Farms, Inc.; and a partnership with Nuevolution A/S, which gives admittance to Nuevolution's Chemetics stage science innovation.
Lexicon Pharmaceuticals has raised $320M across 4 funding rounds on record, the most recent an undisclosed round of $55.0M announced in May 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lexicon Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: May 2026.
Lexicon Pharmaceuticals Funding Rounds
Lexicon Pharmaceuticals raised $150M in a Post-IPO Debt announced in Mar 2022.
4 months later, a Post-IPO Equity of $42.9M was announced in Jul 2022.
11 months later, an undisclosed round of $72.2M was announced in Jun 2023.
2.9 years later, an undisclosed round of $55.0M was announced in May 2026.
Lexicon Pharmaceuticals Founders and Leadership Team
Contact details for the Lexicon Pharmaceuticals team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Lexicon Pharmaceuticals Funding Compared to Other Biotechnology Startups
Lexicon Pharmaceuticals' latest round of $55.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lexicon Pharmaceuticals in Biotechnology and The Woodlands
Companies Similar to Lexicon Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Lexicon Pharmaceuticals Funding FAQs
What does Lexicon Pharmaceuticals do?
Vocabulary Pharmaceuticals, Inc. (previously Lexicon Genetic) a biopharmaceutical organization, centers around the disclosure and improvement of drug items for the treatment of human infection, including immunology, digestion, cardiology, and ophthalmology. The organization's medication competitors incorporate LX1031, which has finished Phase II clinical preliminaries for the treatment of peevish entrail condition and other gastrointestinal problems; LX4211 that has finished Phase II clinical preliminaries to treat type 2 diabetes; LX2931, which is in Phase II clinical preliminaries for the treatment of rheumatoid joint pain and other immune system illnesses; and LX1032 that has finished Phase II clinical preliminaries to treat the side effects related with carcinoid disorder. It likewise has a preclinical improvement drug competitor, LX7101, for the treatment of glaucoma. The organization has drug disclosure coalitions with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It likewise has drug improvement funding cooperation with Symphony Icon; joint effort concurrence with Taconic Farms, Inc.; and a partnership with Nuevolution A/S, which gives admittance to Nuevolution's Chemetics stage science innovation.
How much funding has Lexicon Pharmaceuticals raised?
Lexicon Pharmaceuticals has raised $320M across 4 rounds on record. The most recent is an undisclosed round of $55.0M announced in May 2026.
When did Lexicon Pharmaceuticals last raise funding?
Lexicon Pharmaceuticals' most recent funding round on record is an undisclosed round of $55.0M, announced in May 2026.
Who founded Lexicon Pharmaceuticals?
FundedIQ lists Mike Exton (Founder) at Lexicon Pharmaceuticals.
Who is the CEO of Lexicon Pharmaceuticals?
Lonnel Coats is listed as CEO at Lexicon Pharmaceuticals.
Where is Lexicon Pharmaceuticals headquartered?
Lexicon Pharmaceuticals is based in The Woodlands, Texas, United States.
How many employees does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals is in the 251-500 employee band.
How does Lexicon Pharmaceuticals' funding compare to other Biotechnology startups?
Lexicon Pharmaceuticals' latest round of $55.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Lexicon Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lexicon Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.